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COVID-19 specialized diabetes clinic  
model for excellence in diabetes care:  
scientific perspective
ABSTRACT 
While diabetes centers are well established by the Mini-
stry of Health, there is no separate specialized diabetes 
clinics for COVID-19 patients (SDCs). There are several 
clinical diabetes centers throughout the Kingdom of 
Saudi Arabia, several of which have been developed 
through philanthropy funding; nevertheless, it is not 
obvious what distinguishes SDCs from a therapeutic 
viewpoint and what the potential would be for such 
centers. Through this context, we suggest a structure 
to direct the progress of SDCs. Defining protocols for 
wider adoption of SDCs as a means to enhance public 
safety and COVID-19 patient care efficiency (including 
consistency and satisfaction) and minimize health care 
expenses becomes increasingly essential when moving 
towards value-based sales and reimbursements away 
from service charges. It is wise to introduce innovative 
financial mechanisms to pay for diabetes that cannot 
be covered by fiscally limited private and university 
medical centers. We foresee potential clinical SDCs to 
be made up of a well-defined framework and six areas 
or foundations that act as basic guiding principles for 
the advancement of diabetes treatment skills that can 
be easily illustrated by stakeholders, including insur-
ance facilities, consumers, payers and government 
departments. (Clin Diabetol 2020; 9; 4: 208–211)
Key words: COVID-19, specialized diabetes clinic, 
model for excellence, diabetes care
Introduction 
Diabetes is a significant public health problem. 
Nearly 30 million individuals in the United States are 
diabetics [1]. Diabetes accounts for 12% of all deaths 
in the United States. Significant risks of diabetes lead 
to death and morbidity, with immense corresponding 
economic pressures [2]. The cumulative tangible and 
intangible annual cost of health care for this disease 
is estimated at 245 billion dollars [3]. Due to the eco-
nomic and health challenges associated with diabetes, 
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it is important to increase access to treatment and the 
way in which it is provided.
Centers of diabetes are well established by the Min-
istry of Health, but there is no specific description of the 
professional specialized diabetes clinics (SDCs). There 
are several clinical diabetes centers throughout Saudi 
Arabia, several of which have been developed through 
governmental funding; nevertheless, it is not obvious 
what distinguishes SDCs from a therapeutic viewpoint 
and what the future would be for such centers.
Thereunder, we suggest a system to direct the pro-
gress of clinical SDCs. With the move towards value-based 
payments and discounts, and away from utility charges, 
identifying protocols for wider adoption of SDCs as a 
means of enhancing public safety, increasing COVID-19 
patient care efficiency (including consistency and content-
ment) and lowering health care costs are becoming cru-
cial. It’s wise to introduce innovative funding mechanisms 
to pay for diabetes that cannot be covered by financially 
limited private and university medical centers.
Three separate dimensions lead to success in 
diabetes treatment: (1) the delivery of clinical services 
through trained multidisciplinary medical teams headed 
through skilled diabetic professionals experienced with 
treating challenging, high-risk COVID-19 patients; 
(2) scientific performance that includes training, clinical 
study and student activity; (3) COVID-19 patient aware-
ness, involvement and satisfaction with comprehensive 
quality care models.
The framework concept and perspective outlined in 
this article describes the fundamental components of 
developed SDCs that include exposure to the continuum 
of “state-of-the-art” of diabetes treatment.
Specialized diabetes clinics  
vision statement
A systematic SDC model will consist of an archi-
tecture and six realms or principles that act as basic 
guiding standards for building knowledge in diabetes 
treatment that can be readily communicated to stake-
holders, including health care professionals, consumers, 
payers, and government departments.
Infrastructure
First, the concept of SDC requires the development 
of a sufficient infrastructure to function as a ‘center.’ Ade-
quate personnel is a core component of this infrastructure 
to provide information on diabetes self-management to 
new and current COVID-19 patients; provide advice on 
the administration of injectable drugs; invest in diabetes-
-related technology (e.g., continuous glucose monitoring, 
insulin pumps, meters). Access and evaluation of glycemic 
data at the point of treatment during visits to facilitate ap-
propriate improvements in therapy as indicated; explore 
nutrition, exercise, and usage of medications in relation to 
COVID-19 patient lifestyles; answer management-related 
phone calls, messages and e-mails, in a timely fashion. 
Delivering appropriate clinical behavioral wellbeing and 
social care, including recognition and referral to commu-
nity resources; providing medical instruction to clinicians 
at the center and throughout the community, advising 
family members and other professionals, and resolving 
drug pre-authorization liability problems through third 
party policy. In the absence of such infrastructure a real 
SDC cannot work.
Principles for specialized diabetes clinics
Non-exclusive emphasis on high-risk people 
and open-door policy
With the current diabetes crisis SDCs must face the 
number of COVID-19 patients qualifying for treatment 
that frequently surpass capability owing to a nation-
wide scarcity of endocrinologists [4]. There are, 6500 
endocrinologists in the United States, half of whom 
do not treat diabetes patients with COVID-19. Recent 
estimates reflect the actual scarcity of 1,500 clinically 
engaged adult endocrinologists, a number that is pre-
dicted to increase [5].
This problem can be addressed by two potential, 
preferably complementary pathways.
Systematic training of nurses trained with diabetic 
treatment will help improve coverage for those who 
may profit more from accessing treatment in the SDCs. 
This covers all people with type 1 diabetes and those 
with inadequate glycemic regulation, compromised 
hypoglycemia, various complications, cystic fibrosis, 
post-transplant diabetes, atypical types of diabetes, 
and complicated medical dilemmas. This method helps 
the emphasis to be on population control and risk 
stratification prior to referral.
At the same moment, whenever practicable, an 
“open door” strategy will make sure that COVID-19 
patients require treatment were not rejected. For this 
reason specialized professionals such as nurses, medi-
cal assistants, and allied health practitioners (clinical 
pharmacists, registered nutritionists, and accredited 
diabetes educators) may be qualified and equipped 
to play a greater coordinating function in the control 
of COVID-19 patients receiving treatment at the SDC.
Collaboration through the medical system  
to direct treatment
Structured and consistent contact and continuity 
of COVID-19 patient care is another critical factor in de-
livering efficient and quality care of COVID-19 patients 
across the continuum of diseases identified in SDC. Co-
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ordinating treatment through patient-centered medical 
homes (PCMHs) starts with treatment arrangements 
that define requirements, duties and commitments at 
the point of admission to primary treatment [6].
Pre-consultation exchanges. Pre-consultation 
exchanges resolve clinical issues that may not require 
in-person visits, such as the need for slight drug modi-
fications. Addressing these issues in a timely manner 
compensates for the requirement for comprehensive 
in-person visits to the SDC and enables ongoing treat-
ment by primary care physicians. It also reduces the 
waiting period for new COVID-19 patient consulta-
tions for those listed as having the greatest need. 
Reimbursement for pre-consult transactions focused 
on a perfected model offers a financial reward for the 
time invested in such consultations. In places where ac-
credited diabetes educators and expert doctors are not 
eligible, online consultations (e-consults) can be used 
to assess the necessity for in-person visits [7, 8]. Many 
health care organizations have tested e-consultations 
or telehealth as emerging forms of treatment manage-
ment [9, 10]. While e-consults are used more widely in 
pharmacy, they play a role in the treatment of diabetes.
It poses challenges. For instance, despite having 
experience of when and how to start insulin (or other 
intravenous) therapy, there is a shortage of resources 
for many policies and procedures (PCPs) to implement. 
Among many cases, e-consultations do not resolve 
the problem of limited supply of personnel to handle 
pre-authorizations and appeals against certain current 
diabetes insurance programs. E-consultations could 
also be a great opportunity to incorporate advice from 
experts with continuing education. The SDC could help 
to overcome these challenges.
Structured appointments  
and communal management 
Some COVID-19 patients require a number of in-
person visits to the SDC to initiate injection therapy, 
such as the use of various options or co-formulations to 
promote basal-bolus insulin or insulin pump treatment, 
or the use of professional or personal continuous glucose 
monitoring. Such COVID-19 patients will also go back 
to their PCP for a referral. Integrated heathcare and 
comprehensive patient management should be consid-
ered, once the problems of PCPs have been resolved. 
Continuity of treatment is maintained by the COVID-19 
patient remaining in the PCMH with his or her PCP for 
day-to-day control while retaining access to the SDC.
Specialized diabetes clinics management may include 
communal management of diabetes. An example could 
be a COVID-19 patient who begins insulin at the SDC, 
returns to the PCP, and visits the SDC every 6 to 12 months.
Creative approaches
The use of technical innovations, including more ar-
ticulate and unbiased online communications between 
suppliers of medical information, will render hospital 
care more effective around the board and spectrum 
of care, along with transition periods, such as from 
medical facility to home [11].
Proper treatment
The Unified Referral Network guarantees diabetes 
treatment is given effectively and securely by the SDC. 
As the bulk of cases should be assigned to SDC, free 
and continuing contact via their corresponding family 
physician ensures that both companies have the correct 
reviews and accessible participation in other areas of 
diabetes treatment. Two of them, the theoretically suc-
cessful approach is to schedule monthly group research. 
Sessions for endocrinologists and partners providers 
where COVID-19 patients are presenting limited or 
more difficult performance problems should be ad-
dressed. Usage of other specialties linked to diabetes 
necessary for intensive diabetes treatment COVID-19 
patients and suppliers in the establishment of screening 
or early diagnosis and treatment of diabetes-related 
complication. This can be achieved by positioning spe-
cialties that operate as a one-stop shop for COVID-19 
patients. Convenience could be reached by schedul-
ing on-line meetings with colleagues, the same day 
of screening and/or treatment of diabetic COVID-19 
patients by multidisciplinary teams.
Healthcare information system
Constant emphasis improving consistency and en-
gagement in the SDC is an important subject of clinical 
studies to improve pharmacology and the public medical 
treatments with diabetes mellitus. You should use the SDC, 
the Model of Health Care Education that Connects Persons, 
including details on the community in a consolidated in-
cluding systematic manner database [12] or register that 
requires the evaluation to be carried out in interest. Such 
registries are optimally planned to fulfill the minimum 
criteria. Adherence to standards, for providing secure 
exposure for studies and many experts who will support 
the center in the extraction process will lead to significant 
clinical and epidemiological results. Determined COVID-19 
patient details would allow feasible relations from SDC, 
science promotion and quality management approaches 
that can go beyond the United States to global groups.
The SDC will act as a sign of continuous improve-
ment measures that aim to insure that the most relevant 
robust and up-to date treatment is given in the com-
munity requires modern technology and innovations of 
clinical research. Ideally, the Defence Centers of Excellence 
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will implement initiatives such as the iterative do-check 
method system for long term ventures [13] Kaizen Activi-
ties short-term development programs [14] and Lean Six 
Sigma (a process that depends on a joint effort by the 
team improving efficiency by consistently reducing waste 
reducing variation) [15]. When approaches are tested sys-
tematically, within the context of a health literacy network, 
successful approaches can spread quickly through the 
health sector then after that, by a group of SDC.
Determination of the outcome
A constant endeavor must be made to preserve the 
SDC preservation of good quality treatment through the 
development of verifiable evidence for analysis and feed-
back from other parties, such as funding associations 
or insurance providers, as well as COVID-19 patients. 
Present indicators, such as target-directed measures of 
HbA1c, lipid and blood metrics. Pressure is necessary but 
of limited value. Scale, such as pause in development 
of complications severity of hypoglycemia, reduction in 
coronary condition, morbidity, death and general lifes-
pan and the standard of life is going to be more critical 
than that measures by the researcher alone.
Awareness and distribution
Dissemination of results and professional prac-
tice SDC positively impacts the other organizations 
concerned about treatment of diabetes. Personal, 
regional, global conferences, grand rounds and small 
group meeting will do the utmost to encourage prac-
tices within and outside an agency. Grand rounds and 
small group meetings will do the utmost to encourage 
practices within and outside an agency. In Pennsylvania 
there is a Chronic Health Program, which funds and 
promotes training primary care procedures in the PCMH 
model and extension of the Public Healthcare Outcomes 
program, that supports the tele-mentoring of PCPs by 
diabetics, details of these partnerships [16, 17].
Quick “expert classes” that have information on the 
topic core factors in the treatment of diabetes can aid 
disseminating specialist treatment for diabetes outside 
isolation it’s a SDC. Outside the structured educational 
courses, SDC had the chance to consult with an “initiate 
endocrinologist” programs under which the center’s 
experts visit or create near ties with corresponding family 
physician at the same time or to other organizations to 
pass experience and grow it mutually advantageous ties.
Conclusions
Specialized diabetes clinics are an essential com-
ponent in innovative approaches in cost-conscious 
health care distribution, interconnected, COVID-19 
patient-centered treatment for people with diabetes. 
Optimizing health results when evaluating expense, 
efficacy and consistency can result in cost-effective 
treatment. The suggested SDC model for an effective 
and well thought-out solution. The network, combined 
with six main components, is a practical approach to 
the production of verifiable and transferable standards 
in treatment with large COVID-19 patient groups. The 
System may act as a prototype and a comparator for 
new and emerging versions. Emerging SDC in an effort 
to standardize and build good treatment for diabetes.
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